Article: FDA Clears VaxGen's IND for an Attenuated Smallpox Vaccine Candidate.

VaxGen, Inc. (Pink Sheets: VXGN.PK) announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for the company's candidate smallpox vaccine, LC16m8.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

The effective IND will allow VaxGen to begin clinical development of LC16m8 with the objective of meeting the U.S. government's stated interest in acquiring an emergency stockpile of an attenuated smallpox vaccine(1) and licensing the product for commercial sales. The U.S. government has indicated that it anticipates spending $1.9 billion to establish and maintain a stockpile of ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!